Abstract LBA10
Background
We report the first Phase 3 primary results for sotorasib (soto), a KRASG12C-inhibitor, plus panitumumab (pani), an anti-EGFR antibody, vs standard of care (SOC) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC.
Methods
In the CodeBreaK 300 (NCT05198934) global, open label study, 160 pts with chemorefractory KRAS G12C-mutated mCRC were randomized 1:1:1 to soto 960 mg daily plus pani 6 mg/kg IV (soto960+pani; n=53), soto 240 mg daily plus pani 6 mg/kg IV (soto240+pani, n=53), or investigator’s choice of TAS-102 or regorafenib (n=54). Primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1. Key secondary endpoints included ORR, DRR, and DCR.
Results
The study met its primary endpoint. Both soto+pani arms demonstrated statistically significant superior PFS compared to SOC: soto960+pani HR=0.49 (95% CI: 0.30, 0.80; p=0.006), and soto240+pani HR=0.58 (95% CI: 0.36, 0.93; p=0.03). Secondary efficacy endpoints are shown in the table. OS was immature at data cutoff. Grade ≥3 TRAEs that occurred in ≥5% pts were dermatitis acneiform (11.3%), hypomagnesaemia (5.7%), and rash (5.7%) for soto960+pani; hypomagnesaemia (7.5%), diarrhoea (5.7%) for soto240+pani; and neutropenia (23.5%), anaemia (5.9%), and hypertension (5.9%) for SOC. There were no fatal TRAEs. Table: LBA10
Efficacy by BICR
Soto960+Pani n=53 | Soto240+Pani n=53 | SOC n=54 | |
Median PFS, months (95% CI) | 5.6 (4.21, 6.31) | 3.9 (3.71, 5.75) | 2.2 (1.94, 3.91) |
ORR, % (95% CI) | 26.4 (15.3, 40.3) | 5.7 (1.2, 15.7) | 0 (0.0, 6.6) |
Number of responders | 14 | 3 | 0 |
Median DOR, months (range) | 4.4 (1.9+, 6.0+) | NR (1.8+, 3.8+) | -- |
DCR, % (95% CI) | 71.7 (57.7, 83.2) | 67.9 (53.7, 80.1) | 46.3 (32.6, 60.4) |
CI, confidence interval; DCR, disease control rate; DOR, duration of response; NR, not reached; ORR, objective response rate
Conclusions
In the first phase 3 study for a KRASG12C-inhibitor plus an anti-EGFR antibody in chemorefractory mCRC, the primary endpoint was met and both doses of soto+pani showed superior PFS vs SOC. Soto960+pani demonstrated clinically meaningful benefit across PFS and key secondary endpoints (ORR, DCR, DOR) and was tolerable with lower rates of Grade ≥3 TRAEs vs SOC.
Clinical trial identification
NCT05198934.
Editorial acknowledgement
Medical writing support was provided by Christopher Nosala, PhD (Amgen Inc.).
Legal entity responsible for the study
Amgen Inc..
Funding
Amgen Inc..
Disclosure
F. Pietrantonio: Financial Interests, Personal, Advisory Board: Amgen, Merck-Serono, MSD, Bayer, Organon, Astellas; Financial Interests, Personal, Invited Speaker: Amgen, Merck-Serono, BMS, Lilly, Servier, Bayer, Pierre-Fabre, AstraZeneca, Astellas; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca, Incyte, Agenus. L. Salvatore: Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Personal, Advisory Role: Pierre-Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD; Financial Interests, Personal, Invited Speaker: Takeda, Perre-Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD; Financial Interests, Personal, Advisory Board: Pierre-Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD. T. Esaki: Financial Interests, Personal, Invited Speaker: Chugai, Taiho, EP force, MSD, Daiichi Sankyo, Eli Lilly, Ono, Bristol; Financial Interests, Institutional, Research Grant: MSD, Novartis, Ono, Chugai, Nihon Kayaku, IQVIA, Daiichi Sankyo, Syneos Health Clinical, Pfyzer, Dainippon Sumitomo, Quintiles, Eli Lilly, Parexel, Astellas, Astellas Amgen Biopharma, Asahikasei Pharma, Eisai, Bayer; Financial Interests, Institutional, Funding: Chugai, Nihon Kayaku. D.P. Modest: Financial Interests, Personal, Invited Speaker: Amgen, Servier, Merck, Onkowissen, MSD, BMS, AstraZeneca, PierreFabre, Lilly, Cureteq, GSK, Seagen, Medison, COR2ED, JE, 21up; Financial Interests, Personal, Advisory Board: Amgen, Servier, Merck, MSD, BMS, Incyte, Takeda, G1, Onkowissen, PierreFabre, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Coordinating PI: Servier. D. Paez: Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Personal, Advisory Role: Amgen, Novartis, BMS; Financial Interests, Personal, Invited Speaker: Amgen, Novartis, BMS. J. Taieb: Financial Interests, Personal, Advisory Board: MSD, Astellas, Merck, Servier, Pierre Fabre, Amgen, BMS, Novartis, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, BMS, Merck, MSD, Novartis; Non-Financial Interests, Leadership Role, President of the scientific committee of the ARCAD foundation until end 2022: ARCAD Foundation; Non-Financial Interests, Leadership Role, Chair of the ARCAD pancreas research group: ARCAD Foundation; Non-Financial Interests, Leadership Role, Member of the administrative council, the scientific committee, the executive board and responsible for the international relationships /partnership for FFCD in the prodige intergroup: Federation Francophone de Cancerologie Digestive (FFCD). M.V. Karamouzis: Financial Interests, Personal, Invited Speaker: BMS, Servier, Ipsen, Astellas, Sanofi, AstraZeneca; Financial Interests, Personal, Advisory Board: MSD, Amgen, Specialty Therapeutics, Pierre Fabre. E. Ruiz: Financial Interests, Personal, Advisory Board: Roche, Amgen, BMS, Bayer; Financial Interests, Personal, Invited Speaker: Roche, Merck; Financial Interests, Institutional, Invited Speaker, gastric cancer talk: Astellas. T.W. Kim: Financial Interests, Institutional, Research Grant: Genentech. Y. Kuboki: Financial Interests, Personal, Invited Speaker: Taiho, Lilly, Takeda; Financial Interests, Personal, Advisory Role: Incyte, Takeda, Boehringer, Amgen, Abbie; Financial Interests, Institutional, Research Grant: Taiho, Astelas, Lilly, Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, Abbie, Amgen, Merck, Hengrui. D. Cunningham: Financial Interests, Institutional, Research Grant: MedImmune, Clovis, Eli Lilly, 4SC, Bayer, Celgene, Leap, Roche; Non-Financial Interests, Personal, Advisory Role: OVIBIO. K. Yeh: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, PhytoHealth, Novartis, ONO, Merck, AstraZeneca; Non-Financial Interests, Member: American Society of Clinical Oncology, American Association for Cancer Research. E. Chan: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks or ownership: Amgen Inc.. J. Chao: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks or ownership: Amgen Inc.. N. Strydom: Financial Interests, Personal, Full or part-time Employment: Amgen Inc., Amgen Inc.; Financial Interests, Personal, Stocks or ownership: Amgen Inc., Amgen Inc.. Y. Saportas: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks or ownership: Amgen Inc.. Q. Tran: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks or ownership: Amgen Inc.. C. Cremolini: Financial Interests, Personal, Advisory Board: Roche, MSD, Amgen, Pierre Fabre, Nordic Pharma; Financial Interests, Personal, Invited Speaker: Bayer, Servier, Merck Serono; Financial Interests, Institutional, Coordinating PI: Roche, Bayer, Servier, Merck; Financial Interests, Institutional, Local PI: seagen, Hutchinson. M. Fakih: Financial Interests, Personal, Advisory Board, Consultant: AstraZeneca, Bayer Corporation, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, One meeting: Eisai Oncology; Financial Interests, Personal, Advisory Board, One meeting: Entos, Merck, Seattle Genetics, Xenthera; Financial Interests, Personal, Advisory Board, Also Editorial Boards & Consulting: Mirati Therapeutics; Financial Interests, Personal, Advisory Board: Nouscom, Roche / Genentech; Financial Interests, Personal, Advisory Board, Consulting: Pfizer, Taiho Oncology; Financial Interests, Institutional, Research Grant: AgenusBio, Genentech / imCORE, Verastem. All other authors have declared no conflicts of interest.
Resources from the same session
LBA6 - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Presenter: Thomas Powles
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
LBA7 - Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
Presenter: Michiel van der Heijden
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA6 and LBA7
Presenter: Andrea Apolo
Session: Presidential 2
Resources:
Slides
Webcast
LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
Presenter: Mary McCormack
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Ignace Vergote
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8 and LBA9
Presenter: Krishnansu Tewari
Session: Presidential 2
Resources:
Slides
Webcast
Invited Discussant LBA10
Presenter: Miriam Koopman
Session: Presidential 2
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Presidential 2
Resources:
Webcast